Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, gives an overview of the ARROW study (NCT03037385), which was designed to evaluate the safety, tolerability and preliminary antineoplastic activity of pralsetinib in patients with medullary thyroid cancer, RET-altered non-small cell lung cancer (NSCLC) and other RET-altered solid tumors. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).